title: Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis.
abstract: OBJECTIVE
  This study was aimed to investigate the effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on the acute exacerbation of idiopathic pulmonary fibrosis (IPF).
  
  
  METHODS
  Six patients with a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) who developed acute exacerbation were included in this study. Although five of six patients were treated with high-dose corticosteroid therapy, mechanical ventilation was necessary for all six patients due to severe respiratory failure. Blood endotoxin levels were undetectable in all patients. PMX treatment was performed on these six patients.
  
  
  RESULTS
  In four of six patients, alveolar-arterial difference of oxygen (AaDO(2)), serum KL-6 and lactate dehydrogenase (LDH) were improved after PMX treatment. These four patients were successfully weaned from mechanical ventilation and survived more than 30 days after the initial PMX treatment.
  
  
  CONCLUSIONS
  These data suggest a potential beneficial effect of PMX treatment on acute exacerbation of IPF.
authors.affiliation: 4th Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi Bunkyo-ku, Tokyo 113-8603, Japan.
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Seo
authors.forename: Shinji
authors.initials: S
authors.lastname: Abe
authors.forename: Misuzu
authors.initials: M
authors.lastname: Kurahara
authors.forename: Daisuke
authors.initials: D
authors.lastname: Okada
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Saito
authors.forename: Jiro
authors.initials: J
authors.lastname: Usuki
authors.forename: Arata
authors.initials: A
authors.lastname: Azuma
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Koizumi
authors.forename: Shoji
authors.initials: S
authors.lastname: Kudoh
mesh_terms: D000208:Acute Disease; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D018396:Mucin-1; D009077:Mucins / Q000097:blood; D010100:Oxygen / Q000032:analysis; D010865:Pilot Projects; D011112:Polymyxin B / Q000008:administration & dosage*; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000628:therapy; D012121:Respiration, Artificial; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D005938:Glucocorticoids; C060192:MUC1 protein, human; D018396:Mucin-1; D009077:Mucins; D007770:L-Lactate Dehydrogenase; D011112:Polymyxin B; D010100:Oxygen